Isis Pharmaceuticals (ISIS)

Korea Institute of Toxicology

In March 2007, we entered an agreement with the Korea Institute of Toxicology, or KIT.  Under the agreement, at our request, KIT will perform toxicology studies on our drugs at reduced preclinical costs in exchange for a nominal royalty. KIT has conducted toxicology and other IND-enabling studies for our ISIS-CRPRx program, thereby enabling us to initiate a Phase 1 safety study for ISIS-CRPRx in August 2008.  Our relationship with KIT allows for the potential to perform toxicology studies on a number of our other drugs at a significantly reduced cost to us. We are only required to pay KIT when we engage them to perform studies for us.

Korea Institute of Toxicology

In March 2007, we entered an agreement with the Korea Institute of Toxicology, or KIT.  Under the agreement, at our request, KIT will perform toxicology studies on our drugs at reduced preclinical costs in exchange for a nominal royalty. KIT has conducted toxicology and other IND-enabling studies for our ISIS-CRPRx program, thereby enabling us to initiate a Phase 1 safety study for ISIS-CRPRx in August 2008.  Our relationship with KIT allows for the potential to perform toxicology studies on a number of our other drugs at a significantly reduced cost to us. We are only required to pay KIT when we engage them to perform studies for us.

Korea Institute of Toxicology

In March 2007, we entered
an agreement with the Korea Institute of Toxicology, or KIT.  Under the agreement, at our request, KIT will
perform toxicology studies on our drugs at reduced preclinical costs in
exchange for a nominal royalty. KIT has conducted toxicology and other IND-enabling
studies for our ISIS-CRPRx program, thereby enabling us to initiate a
Phase 1 safety study for ISIS-CRPRx in August 2008.  Our relationship with KIT allows for the
potential to perform toxicology studies on a number of our other drugs at a
significantly reduced cost to us. We
are only required to pay KIT when we engage them to perform studies for us.

Korea Institute of Toxicology

In March 2007, we entered
an agreement with the Korea Institute of Toxicology, or KIT.  Under the agreement, at our request, KIT will
perform toxicology studies on our drugs at reduced preclinical costs in
exchange for a nominal royalty. KIT has conducted toxicology and other IND-enabling
studies for our ISIS-CRPRx program, thereby enabling us to initiate a
Phase 1 safety study for ISIS-CRPRx in August 2008.  Our relationship with KIT allows for the
potential to perform toxicology studies on a number of our other drugs at a
significantly reduced cost to us. We
are only required to pay KIT when we engage them to perform studies for us.

Korea Institute of Toxicology

In March 2007, we entered
an agreement with the Korea Institute of Toxicology, or KIT.  Under the agreement, at our request, KIT will
perform toxicology studies on our drugs at reduced preclinical costs in
exchange for a nominal royalty. KIT has conducted toxicology and other IND-enabling
studies for our ISIS-CRPRx program, thereby enabling us to initiate a
Phase 1 safety study for ISIS-CRPRx in August 2008.  Our relationship with KIT allows for the
potential to perform toxicology studies on a number of our other drugs at a
significantly reduced cost to us. We
are only required to pay KIT when we engage them to perform studies for us.

Korea Institute of Toxicology

In March 2007, we entered an agreement with the Korea Institute of Toxicology, or KIT.  Under the agreement, at our request, KIT will perform toxicology studies on our drugs at reduced preclinical costs in exchange for a nominal royalty. KIT has conducted toxicology and other IND-enabling studies for our ISIS-CRPRx program, thereby enabling us to initiate a Phase 1 safety study for ISIS-CRPRx in August 2008.  Our relationship with KIT allows for the potential to perform toxicology studies on a number of our other drugs at a significantly reduced cost to us. We are only required to pay KIT when we engage them to perform studies for us.

Korea Institute of Toxicology

In March 2007, we entered an agreement with the Korea Institute of Toxicology, or KIT.  Under the agreement, at our request, KIT will perform toxicology studies on our drugs at reduced preclinical costs in exchange for a nominal royalty. KIT has conducted toxicology and other IND-enabling studies for our ISIS-CRPRx program, thereby enabling us to initiate a Phase 1 safety study for ISIS-CRPRx in August 2008.  Our relationship with KIT allows for the potential to perform toxicology studies on a number of our other drugs at a significantly reduced cost to us. We are only required to pay KIT when we engage them to perform studies for us.

Korea Institute of Toxicology

In March 2007, we entered
an agreement with the Korea Institute of Toxicology, or KIT.  Under the agreement, at our request, KIT will
perform toxicology studies on our drugs at reduced preclinical costs in
exchange for a nominal royalty. KIT has conducted toxicology and other
IND-enabling studies for our ISIS-CRPRx program, thereby enabling us to initiate a
Phase 1 safety study for ISIS-CRPRx in August 2008.  Our relationship with KIT allows for the
potential to perform toxicology studies on a number of our other drugs at a
significantly reduced cost to us. We
are only required to pay KIT when we engage them to perform studies for us.

Korea Institute of Toxicology

In March 2007, we entered
an agreement with the Korea Institute of Toxicology, or KIT.  Under the agreement, at our request, KIT will
perform toxicology studies on our drugs at reduced preclinical costs in
exchange for a nominal royalty. KIT has conducted toxicology and other
IND-enabling studies for our ISIS-CRPRx program, thereby enabling us to initiate a
Phase 1 safety study for ISIS-CRPRx in August 2008.  Our relationship with KIT allows for the
potential to perform toxicology studies on a number of our other drugs at a
significantly reduced cost to us. We
are only required to pay KIT when we engage them to perform studies for us.

Korea Institute of Toxicology

In March 2007, we entered
an agreement with the Korea Institute of Toxicology, or KIT.  Under the agreement, at our request, KIT will
perform toxicology studies on our drugs at reduced preclinical costs in
exchange for a nominal royalty. KIT has conducted toxicology and other
IND-enabling studies for our ISIS-CRPRx program, thereby enabling us to initiate a
Phase 1 safety study for ISIS-CRPRx in August 2008.  Our relationship with KIT allows for the
potential to perform toxicology studies on a number of our other drugs at a
significantly reduced cost to us. We
are only required to pay KIT when we engage them to perform studies for us.